Who are Tramal®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tramadol /acetaminophen, Tramadol IV (Tradonal® IV), Tramadol HCl, Tramadol PR oral, Tramadol OAD, Tramadol 50.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tramal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tramal® — Competitive Intelligence Brief

Tramal® (Tramal®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic opioid analgesic. Area: Pain Management.

marketed Synthetic opioid analgesic Mu opioid receptor; norepinephrine transporter; serotonin transporter Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Tramal® (Tramal®) — Apsen Farmaceutica S.A.. Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and inhibits the reuptake of norepinephrine and serotonin to provide pain relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tramal® TARGET	Tramal®	Apsen Farmaceutica S.A.	marketed	Synthetic opioid analgesic	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol /acetaminophen	Tramadol /acetaminophen	Johnson & Johnson Taiwan Ltd	marketed	Opioid analgesic combination	Mu opioid receptor; norepinephrine transporter; serotonin transporter; cyclooxygenase
Tramadol IV (Tradonal® IV)	Tramadol IV (Tradonal® IV)	University Hospital, Ghent	marketed	Opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol HCl	Tramadol HCl	Labopharm Inc.	marketed	Synthetic opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol PR oral	Tramadol PR oral	Pfizer	phase 3	Opioid analgesic with monoamine reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol OAD	Tramadol OAD	Labopharm Inc.	phase 3	Opioid analgesic with norepinephrine-serotonin reuptake inhibition	Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol 50	Tramadol 50	Grünenthal GmbH	phase 3	Synthetic opioid analgesic	Mu opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic opioid analgesic class)

Apsen Farmaceutica S.A. · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tramal® — Competitive Intelligence Brief. https://druglandscape.com/ci/tramal. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab